



Merz Celebrates a Monumental Milestone: One Million Treatments Worldwide with Ultherapy®

Merz Pharma GmbH & Co. KGaA
Eckenheimer Landstrasse 100
60318 Frankfurt am Main

Global Corporate Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466
Email: mariana.smith@merz.com

www.merz.com

Frankfurt, Germany – May 18, 2017 – Merz Aesthetics, a division of Merz Pharma Group, announced today that Ultherapy® is celebrating the milestone achievement of conducting one million treatments globally. Since its global launch in 2008 and U.S. launch in 2009, the non-invasive ultrasound device has become a game-changer in physician offices worldwide for lifting and tightening skin with its cutting-edge technology. The revolutionary treatment is currently the first and only treatment FDA-cleared to non-invasively lift the eyebrow, neck, and chin, and to improve lines and wrinkles on the décolletage via micro-focused ultrasound. Ultherapy® also conforms to the European level of quality and safety for medical devices.

“It is no surprise that Ultherapy® has reached one million treatments worldwide - it is a favorite treatment that I recommend to patients requesting skin lifting and tightening,” stated Dr. Doris Day, board certified dermatologist and founder of Day Dermatology and Aesthetics. “The technology not only naturally stimulates collagen growth and provides visible results, but also little to no downtime post treatment.”

Making the treatment even more popular amongst physicians, Ultherapy® is the only cosmetic procedure to use ultrasound imaging, which allows physicians to see the layers of tissue targeted during the treatment to ensure the energy is deposited where it will be most beneficial. This unique technology is supported by more than 50 clinical studies, more than 60 published, peer-reviewed papers, and over 100 patents.

“We’re extremely proud to be celebrating this milestone of treating one million patients with Ultherapy® on a global scale,” said Philip Burchard, Chief Executive Officer, Merz Pharma. “Ultherapy® continues to lead in the category due to its breakthrough, award-winning innovation, our dedicated physicians, and consistent patient satisfaction. We look forward to celebrating the next million treatments.”

For more information on Ultherapy®, visit www.global.ultherapy.com

About Merz Pharma Group

With approximately 3,000 employees and 34 subsidiaries, Merz is a leading global provider in the fields of Aesthetics and Neurotoxins. Privately held for more than 100 years, the company is distinguished by its in-house research and development, solid financial strength and continuous growth. In addition to its

PRESS RELEASE



unique portfolio of products for minimally invasive and non-invasive skin rejuvenation and tightening, Merz also develops neurotoxin therapy to treat neurologically induced movement disorders. OTC medicines, dietary supplements and skincare products round off the offerings from the company, which is headquartered in Frankfurt, Germany. In fiscal year 2015/16, the Merz Pharma Group generated revenue of EUR 1,092.9 million. More information is available at www.merz.com.

Media Contact:

Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Tel.: +49 151 4249 1466
E-Mail: mariana.smith@merz.com